Notice of Appeal

Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]

NICE has received an appeal, that fall within one or more of the two strictly limited grounds for appeal, against the Final Draft Guidance on the above technology from the following organisations:

• Orion Pharma UK Ltd

The appeal panel will convene on Tuesday 26 November at 10:00am via Zoom to hear oral representations from the appellants.

Members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing.

Where possible, requests to attend should be made using the registration link that will be available on our website from Wednesday 11 September 2024. The registration period for this appeal will end at 4:00pm on Wednesday 19 September 2024.

Further details relating to public attendance at this appeal are available on the same webpage as above.